Xaga Surgical's research and product development have been the result of a collaborative effort by a diverse and interdisciplinary team. Encompassed by experts in infection control, urology, surgery, pathology, intensive care, medical technology, engineering, prototyping, research, as well as partnerships with several Swedish and international companies it is a true team effort. The orchestrator of this collaborative endeavor has been Andreas Forsvall at Lund University and the final results of our efforts are the products developed by Xaga Surgical.
Xaga's primary goal has been to transition from identifying problems to delivering effective solutions, which have culminated in the products described here. The scientific foundation underpinning these advancements can be explored further in the section below. We have several ongoing trials, stay updated for future results.
Antibiotic resistance is a global crisis, with bacteria and microorganisms evolving to resist antibiotic treatment. Overuse and misuse of antibiotics in human medicine, agriculture, and livestock accelerate this problem. Hospital-acquired infections, often requiring antibiotic treatment, worsen the issue. These infections further envelope already antibiotic-resistant bacteria. Treating such infections becomes costlier and more challenging, leading to prolonged illness and higher mortality rates. A deadly spiral placing antibiotic resistance as one of the top 10 threats to humanity. To tackle this threat, responsible antibiotic use, new antibiotics, and infection prevention are vital.
Xaga Surgical contributes by the most vital step in infection prevention- source control. By developing safer needles we aim to prevent infections and reduce the need to treat already resistant bacteria, breaking the deadly spiral.
.PNG)